MN-KINDEVA-DRUG-DELIVERY
8.5.2024 14:01:35 CEST | Business Wire | Press release
At the recent Respiratory Drug Delivery (RDD) Conference, John Patton, Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, was announced as the winner of the Charles G. Thiel Award. This prestigious award is given once every two years at RDD Conferences to one scientist who has been voted by his or her peers to have pioneered significant developments in one or more aspects of the science and technology surrounding respiratory drug delivery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508931671/en/
Biotechnology scientist and entrepreneur and Kindeva Drug Delivery’s Head of the Scientific Advisory Board, John Patton (second from the left), was named the winner of the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery at this year’s Respiratory Drug Delivery (RDD) Conference. Also pictured (from left to right): Michael Hindle, Ph.D., Professor, School of Pharmacy at Virginia Commonwealth University, Stephen Stein, Scientific Director of Inhalation Product Development at Kindeva, and Milton Boyer, CEO at Kindeva. (Photo: Business Wire)
Patton has been one of the most influential scientists in the field of respiratory drug delivery and is a champion in the field of pulmonary delivery of large molecules and biologics. He has published more than 100 publications, has more than 40 patents, and has founded or co-founded six drug delivery companies, including iPharma Labs, a company that Kindeva acquired in 2022.
“John’s research and development expertise, coupled with the myriad publications he authored, have helped pave the way for respiratory delivery to be utilized by researchers and companies for the treatment of other diseases,” said Kindeva’s Global Chief Commercial Officer, David Stevens. “John’s passion and conviction with respect to the applications of drug delivery to and through the lungs, and in particular his pioneering work progressing pulmonary delivery of biologics, has been nothing short of inspiring. John has made and continues to make a tremendous contribution to both Kindeva and the wider industry. On behalf of all his colleagues at Kindeva, we congratulate John. It is a privilege to work alongside him and benefit from his technical vision and boundless enthusiasm for inhaled medicine.”
Kindeva’s application in inhaled biologics spans complex therapeutic treatments from local to deep lung (systemic) delivery — including lung fibrosis, asthma/COPD, cardiovascular, and infectious diseases — and encompasses a wealth of expertise in developing solutions that address insulin needs, cold chain requirements, and more.
Read more about this award as well as Kindeva’s advancements in biologic drug development.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508931671/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Launches Beta of New AI-Powered Analytical Capabilities in Ask Arthur13.3.2026 12:00:00 CET | Press release
AI-guided analysis helps brands and retailers turn data into decision-ready insights NIQ (NYSE: NIQ), a global leader in consumer intelligence, has launched new AI-powered analytical capabilities in beta within Ask Arthur on the NIQ Discover platform. The expanded experience guides users through end-to-end analysis—helping them identify what matters in the data, understand why trends are occurring, and turn insights into clear, shareable narratives with recommended next steps. As organizations navigate increasing data complexity, the ability to move quickly from insight to action has become essential. Ask Arthur helps shorten analytical processes that once took days or weeks into minutes by surfacing the key drivers behind performance changes and generating decision-ready insights directly within Discover. By connecting analysis, explanation, and storytelling in a single experience, users can move seamlessly from understanding what is happening in the data to determining what to do nex
Reply at NVIDIA GTC: Digital Twins and Physical AI Driving the Next Stage of Industrial Value Creation13.3.2026 11:24:00 CET | Press release
Reply [EXM, STAR: REY] will be present at NVIDIA GTC from 16 to 19 March 2026 in San Jose, California, showcasing how companies can optimise production and logistics processes, scale robotics and sustainably increase industrial performance using digital twin technology and physical AI. The conference is regarded as the most important international meeting point for AI developers, researchers and decision makers. This year, more than 30,000 participants from over 190 countries are expected to attend. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260313000399/en/ By attending NVIDIA GTC, Reply is showcasing how digital simulation and physical automation are already being integrated in practice. Projects for the Otto Group and the industrial edge domain show how physical AI and precise digital twins work together to create new opportunities for industrial value generation. The focus will be on two concrete use cases that demon
Klarna Board Chair Michael Moritz Acquires 3.47 Million Shares for $50 Million13.3.2026 11:05:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today discloses the following transactions by the Chair of its Board of Directors and Chief Product & Design Officer, filed with the U.S. Securities and Exchange Commission on Form 3. Share Purchases Michael Moritz, Chairman, through an associated entity, purchased 3,472,845 ordinary shares between March 3 and March 11, 2026, at an aggregate consideration of $49,913,138.73. David Fock, Chief Product & Design Officer, purchased 27,000 ordinary shares on March 9, 2026, for an aggregate consideration of $388,552.14. Share Sales David Sandström, Chief Marketing Officer, sold 32,703 shares on March 9, 2026, pursuant to a Rule 10b5-1 trading plan, established in 2025. David Sykes, Chief Commercial Officer, sold 23,799 shares on March 13, 2026, pursuant to a separately established Rule 10b5-1 trading plan, established in 2025. Form 3 filings for all transactions are available on the SEC's EDGAR database atwww.sec.gov. Forward-Looking Statements This press release
Intertek Launches Comprehensive Digital Product Passport Services13.3.2026 10:00:00 CET | Press release
Supporting circular economy and regulatory compliance Intertek, a leading Total Quality Assurance provider to industries worldwide, has announced the launch of its enhanced Digital Product Passport (DPP) suite of services. This includes a comprehensive advisory service designed to help manufacturers, brands and retailers navigate the fast-evolving regulatory and sustainability landscape associated with digital product passports and circular economy compliance. Mark Thomas, Executive Vice President, Global Sustainability, Assurance, Agri World and Food at Intertek, said: “With the introduction of regulatory frameworks for improving the sustainability performance of products, companies are facing mounting pressure to implement robust systems for transparency, traceability and sustainability reporting globally. This shift marks a significant regulatory milestone, requiring organisations to strengthen data governance, engage suppliers more effectively and demonstrate credible, verifiable s
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom